This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter | The Motley Fool

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.